A Case of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Dysfunction, and Organomegaly (TAFRO) Syndrome Refractory to Treatment With Combination Therapy of Corticosteroid, Tocilizumab, and Rituximab: A Case Report
Akihiro Ogawa, Kaori Yamaguchi · 2026
Read A Case of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Dysfunction, and Organomegaly (TAFRO) Syndrome Refractory to Treatment With Combination Therapy of Corticosteroid, Tocilizumab, and Rituximab: A Case Report by Akihiro Ogawa, Kaori Yamaguchi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13334406.txt.
Description
Akihiro Ogawa and colleagues report a 2026 case of TAFRO syndrome refractory to triple therapy with steroid, tocilizumab, and rituximab. TAFRO stands for low platelets, swelling, fever, marrow scarring or kidney failure, and enlarged organs. The patient was a earlier healthy 76-year-old man treated with steroids, tocilizumab, and rituximab, yet he developed multiple infections and the disease progressed, ultimately leading to death.
He first presented with both-sided lower leg swelling and was referred for severe kidney failure and high inflammation markers. CT showed mild widespread gland swelling. Bone marrow biopsy showed mild marrow scarring, and a neck lymph node biopsy showed shrunken germinal centers with marked between-follicle blood vessels, features consistent with Castleman-like tissue pattern. Based on those findings, TAFRO syndrome was diagnosed, yet immunosuppressive treatment did not improve renal dysfunction and hemodialysis was initiated. The case documents a resistant course despite triple therapy.
Catalog record
| CREATOR | Akihiro Ogawa, Kaori Yamaguchi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |